![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC25A19 |
Gene summary for SLC25A19 |
![]() |
Gene information | Species | Human | Gene symbol | SLC25A19 | Gene ID | 60386 |
Gene name | solute carrier family 25 member 19 | |
Gene Alias | DNC | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | Q5JPC1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
60386 | SLC25A19 | LZE24T | Human | Esophagus | ESCC | 1.24e-06 | 1.40e-01 | 0.0596 |
60386 | SLC25A19 | P2T-E | Human | Esophagus | ESCC | 3.66e-05 | 5.83e-02 | 0.1177 |
60386 | SLC25A19 | P4T-E | Human | Esophagus | ESCC | 3.33e-06 | 9.16e-02 | 0.1323 |
60386 | SLC25A19 | P9T-E | Human | Esophagus | ESCC | 8.05e-03 | 3.52e-02 | 0.1131 |
60386 | SLC25A19 | P10T-E | Human | Esophagus | ESCC | 5.37e-10 | 1.52e-01 | 0.116 |
60386 | SLC25A19 | P11T-E | Human | Esophagus | ESCC | 2.15e-05 | 1.40e-01 | 0.1426 |
60386 | SLC25A19 | P12T-E | Human | Esophagus | ESCC | 1.59e-06 | 1.23e-01 | 0.1122 |
60386 | SLC25A19 | P15T-E | Human | Esophagus | ESCC | 3.70e-09 | 7.93e-02 | 0.1149 |
60386 | SLC25A19 | P17T-E | Human | Esophagus | ESCC | 1.76e-04 | 1.36e-01 | 0.1278 |
60386 | SLC25A19 | P20T-E | Human | Esophagus | ESCC | 2.89e-12 | 3.74e-01 | 0.1124 |
60386 | SLC25A19 | P21T-E | Human | Esophagus | ESCC | 2.41e-04 | 1.88e-01 | 0.1617 |
60386 | SLC25A19 | P22T-E | Human | Esophagus | ESCC | 4.25e-02 | 3.43e-02 | 0.1236 |
60386 | SLC25A19 | P23T-E | Human | Esophagus | ESCC | 4.74e-10 | 1.62e-01 | 0.108 |
60386 | SLC25A19 | P26T-E | Human | Esophagus | ESCC | 4.61e-07 | 1.65e-01 | 0.1276 |
60386 | SLC25A19 | P27T-E | Human | Esophagus | ESCC | 1.19e-09 | 9.88e-02 | 0.1055 |
60386 | SLC25A19 | P28T-E | Human | Esophagus | ESCC | 6.23e-14 | 2.15e-01 | 0.1149 |
60386 | SLC25A19 | P31T-E | Human | Esophagus | ESCC | 4.68e-07 | 1.32e-01 | 0.1251 |
60386 | SLC25A19 | P32T-E | Human | Esophagus | ESCC | 6.92e-04 | 1.32e-01 | 0.1666 |
60386 | SLC25A19 | P36T-E | Human | Esophagus | ESCC | 1.61e-02 | 1.51e-01 | 0.1187 |
60386 | SLC25A19 | P37T-E | Human | Esophagus | ESCC | 2.97e-03 | 1.37e-01 | 0.1371 |
Page: 1 2 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:00067671 | Esophagus | ESCC | water-soluble vitamin metabolic process | 41/8552 | 59/18723 | 1.84e-04 | 1.17e-03 | 41 |
GO:00067661 | Esophagus | ESCC | vitamin metabolic process | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
GO:00725273 | Esophagus | ESCC | pyrimidine-containing compound metabolic process | 52/8552 | 82/18723 | 9.03e-04 | 4.61e-03 | 52 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A19 | SNV | Missense_Mutation | novel | c.901T>A | p.Phe301Ile | p.F301I | Q9HC21 | protein_coding | deleterious(0.02) | possibly_damaging(0.69) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SLC25A19 | SNV | Missense_Mutation | rs759157320 | c.505G>A | p.Glu169Lys | p.E169K | Q9HC21 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SLC25A19 | SNV | Missense_Mutation | c.500N>T | p.Arg167Met | p.R167M | Q9HC21 | protein_coding | deleterious(0) | benign(0.309) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC25A19 | SNV | Missense_Mutation | rs372219499 | c.428N>A | p.Arg143His | p.R143H | Q9HC21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
SLC25A19 | deletion | Frame_Shift_Del | c.489delN | p.Thr164ProfsTer19 | p.T164Pfs*19 | Q9HC21 | protein_coding | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |||
SLC25A19 | SNV | Missense_Mutation | rs561002779 | c.838N>A | p.Gly280Ser | p.G280S | Q9HC21 | protein_coding | deleterious(0.04) | probably_damaging(0.943) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLC25A19 | SNV | Missense_Mutation | rs141184131 | c.146N>A | p.Arg49His | p.R49H | Q9HC21 | protein_coding | tolerated(0.12) | benign(0.031) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A19 | SNV | Missense_Mutation | novel | c.915N>A | p.Phe305Leu | p.F305L | Q9HC21 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A19 | SNV | Missense_Mutation | rs769095542 | c.604C>A | p.Leu202Met | p.L202M | Q9HC21 | protein_coding | tolerated(0.2) | benign(0.039) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SLC25A19 | SNV | Missense_Mutation | rs535293962 | c.354N>A | p.Phe118Leu | p.F118L | Q9HC21 | protein_coding | tolerated(0.67) | benign(0.026) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |